{"pmid":32340998,"title":"Covid-19: What do we know so far about a vaccine?","text":["Covid-19: What do we know so far about a vaccine?","BMJ","Mahase, Elisabeth","32340998"],"journal":"BMJ","authors":["Mahase, Elisabeth"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32340998","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1136/bmj.m1679","topics":["General Info"],"weight":1,"_version_":1665351883840028673,"score":8.574329,"similar":[{"pmid":31980434,"title":"China coronavirus: what do we know so far?","text":["China coronavirus: what do we know so far?","BMJ","Mahase, Elisabeth","31980434"],"journal":"BMJ","authors":["Mahase, Elisabeth"],"date":"2020-01-26T11:00:00Z","year":2020,"_id":"31980434","week":"20204|Jan 20 - Jan 26","doi":"10.1136/bmj.m308","source":"PubMed","topics":["General Info"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640875422023680,"score":94.319244},{"pmid":32279977,"pmcid":"PMC7118658","title":"What We Know So Far (As of March 26, 2020) About COVID-19-An MRT Point of View.","text":["What We Know So Far (As of March 26, 2020) About COVID-19-An MRT Point of View.","J Med Imaging Radiat Sci","Huang, Shao Hui","32279977"],"journal":"J Med Imaging Radiat Sci","authors":["Huang, Shao Hui"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32279977","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jmir.2020.03.004","source":"PubMed","topics":["General Info"],"weight":1,"_version_":1664636704014729216,"score":78.05864},{"pmid":32265531,"title":"COVID-19 and cancer: what we know so far.","text":["COVID-19 and cancer: what we know so far.","Nat Rev Clin Oncol","Sidaway, Peter","32265531"],"journal":"Nat Rev Clin Oncol","authors":["Sidaway, Peter"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32265531","week":"202015|Apr 06 - Apr 12","doi":"10.1038/s41571-020-0366-2","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664637636036263938,"score":69.582214},{"pmid":32220035,"title":"SARS-CoV-2: What do we know so far?","text":["SARS-CoV-2: What do we know so far?","Acta Physiol (Oxf)","Khedkar, Pratik H","Patzak, Andreas","32220035"],"journal":"Acta Physiol (Oxf)","authors":["Khedkar, Pratik H","Patzak, Andreas"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32220035","week":"202013|Mar 23 - Mar 29","doi":"10.1111/apha.13470","source":"PubMed","topics":["Mechanism","Transmission","Treatment"],"weight":1,"_version_":1664638742917283840,"score":69.179565},{"pmid":32273490,"title":"Coronavirus Disease (COVID-19) in Children - What We Know So Far and What We Do Not?","text":["Coronavirus Disease (COVID-19) in Children - What We Know So Far and What We Do Not?","Pediatric coronavirus disease - 19 (COVID-19) infection is relatively mild when compared to adults, and children are reported to have a better prognosis. Mortality in children appears rare. Clinical features of COVID-19 in children include fever and cough, but a large proportion of infected children appears to be asymptomatic and may contribute to transmission. It remains unclear why children and young adults are less severely affected than older individuals, but this might involve differences in immune system function in the elderly and/or differences in the expression/function of the cellular receptor for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) - Angiotensin converting enzyme 2 (ACE2). Laboratory findings and chest imaging may not be specific in children with COVID-19. Diagnosis is by Reverse transcriptase-Polymerase chain reaction (RT-PCR) testing of upper or lower respiratory tract secretions. This review additionally considers COVID-19 in immunosuppressed children, and also suggests a management algorithm for the few children who appear to present with life threatening infection, including the potential use of antiviral and immunomodulatory treatment. The most significant threat to global child health from SARS-CoV-2 is unlikely to be related to COVID 19 in children, but rather the socio-economic consequences of a prolonged pandemic.","Indian Pediatr","Balasubramanian, S","Rao, Neha Mohan","Goenka, Anu","Roderick, Marion","Ramanan, Athimalaipet V","32273490"],"abstract":["Pediatric coronavirus disease - 19 (COVID-19) infection is relatively mild when compared to adults, and children are reported to have a better prognosis. Mortality in children appears rare. Clinical features of COVID-19 in children include fever and cough, but a large proportion of infected children appears to be asymptomatic and may contribute to transmission. It remains unclear why children and young adults are less severely affected than older individuals, but this might involve differences in immune system function in the elderly and/or differences in the expression/function of the cellular receptor for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) - Angiotensin converting enzyme 2 (ACE2). Laboratory findings and chest imaging may not be specific in children with COVID-19. Diagnosis is by Reverse transcriptase-Polymerase chain reaction (RT-PCR) testing of upper or lower respiratory tract secretions. This review additionally considers COVID-19 in immunosuppressed children, and also suggests a management algorithm for the few children who appear to present with life threatening infection, including the potential use of antiviral and immunomodulatory treatment. The most significant threat to global child health from SARS-CoV-2 is unlikely to be related to COVID 19 in children, but rather the socio-economic consequences of a prolonged pandemic."],"journal":"Indian Pediatr","authors":["Balasubramanian, S","Rao, Neha Mohan","Goenka, Anu","Roderick, Marion","Ramanan, Athimalaipet V"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32273490","week":"202015|Apr 06 - Apr 12","source":"PubMed","topics":["Treatment","Diagnosis","Mechanism","Transmission"],"weight":1,"_version_":1664637190076891136,"score":61.966007}]}